Long-term safety and efficacy of deferasirox (Exjade®) for up to 5years in transfusional iron-overloaded patients with sickle cell disease

Elliott Vichinsky, Françoise Bernaudin, Gian Luca Forni, Renee Gardner, Kathryn Hassell, Matthew M. Heeney, Baba Inusa, Abdullah Kutlar, Peter Lane, Liesl Mathias, John Porter, Cameron Tebbi, Felicia Wilson, Louis Griffel, Wei Deng, Vanessa Giannone, Thomas Coates

Research output: Contribution to journal › Article › peer-review

69 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term safety and efficacy of deferasirox (Exjade®) for up to 5years in transfusional iron-overloaded patients with sickle cell disease'. Together they form a unique fingerprint.

Medicine & Life Sciences